Abstract/References

Successful management of unstable angina in a ravulizumab-treated patient with paroxysmal nocturnal hemoglobinuria

Hiroshi Takahashi, Hirotaka Mori, Masahiko Fukatsu, Takahiro Sano, Kayo Harada, Masayoshi Oikawa, Yasuchika Takeishi, Satoshi Kimura, Hiroshi Ohkawara, Tsutomu Shichishima, Takayuki Ikezoe

Abstract

Ravulizumab is an anti-C5 antibody approved for treating paroxysmal nocturnal hemoglobinuria (PNH). In August 2019, a 77-year-old Japanese man with PNH, who had been on ravulizumab treatment for 2 years, was hospitalized for chest discomfort and malaise. Electrocardiography identified a right bundle block, and elevated serum troponin I and d-dimer suggested ischemic heart disease. Cardiac catheterization revealed severe stenosis in the left anterior descending coronary artery, and intracoronary stenting relieved his chest discomfort. The final diagnosis was unstable angina unrelated to ravulizumab, and the patient’s ravulizumab treatment was uninterrupted with no significant complications of PNH. This case report highlights the importance of continuing complement inhibition therapy during acute coronary events.

The content of research paper

References

1. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood, 124:2804-2811, 2014.
2. Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers, 3:17028, 2017.
3. Ninomiya H, Obara N, Chiba S, et al. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol, 104:548-558, 2016.
4. Hillmen P, Muus P, Roth A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol, 162:62-73, 2013.
5. Nakayama H, Usuki K, Echizen H, Ogawa R, Orii T. Eculizumab dosing intervals longer than 17 days may be associated with greater risk of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Biol Pharm Bull, 39:285-288, 2016.
6. Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood, 125:775-783, 2015.
7. Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors:the 301 study. Blood, 133:530-539, 2019.
8. Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH:the 302 study. Blood, 133:540-549, 2019.
9. Harder MJ, Kuhn N, Schrezenmeier H, et al. Incomplete inhibition by eculizumab:mechanistic evidence for residual C5 activity during strong complement activation. Blood, 129:970-980, 2017.
10. Miyasaka N, Miura O, Kawaguchi T, et al. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab:a Japanese experience and updated review. Int J Hematol, 103:703-712, 2016.
11. Connell NT. Ravulizumab:a complementary option for PNH. Blood, 133:503-504, 2019.
12. Brodsky RA, Peffault de Latour R, Rottinghaus ST, et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica, 106:230-237, 2020.

Figures (1)